Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce Sells 17,500 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $41.74, for a total value of $730,450.00. Following the transaction, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 18th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00.
• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $46.94, for a total transaction of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The shares were sold at an average price of $40.39, for a total transaction of $782,556.25.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA opened at $37.02 on Friday. The firm has a 50 day simple moving average of $45.41 and a 200 day simple moving average of $40.97. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -14.18 and a beta of 1.15. Vera Therapeutics, Inc. has a one year low of $14.20 and a one year high of $51.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Research analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target on the stock. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Wedbush boosted their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Finally, Guggenheim increased their price target on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and an average price target of $63.50.

Institutional Trading of Vera Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in Vera Therapeutics by 28.5% during the 2nd quarter. Renaissance Technologies LLC now owns 147,800 shares of the company’s stock worth $5,347,000 after buying an additional 32,800 shares during the period. First Turn Management LLC lifted its holdings in shares of Vera Therapeutics by 53.3% during the third quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock worth $14,431,000 after purchasing an additional 113,550 shares during the period. Lord Abbett & CO. LLC grew its stake in shares of Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Magnetar Financial LLC acquired a new stake in Vera Therapeutics in the second quarter valued at $652,000. Finally, Victory Capital Management Inc. raised its position in Vera Therapeutics by 202.4% during the 2nd quarter. Victory Capital Management Inc. now owns 33,707 shares of the company’s stock worth $1,220,000 after purchasing an additional 22,560 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.